Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024 08:05 ET
|
Organovo, Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 26, 2024 06:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
A Groundbreaking Milestone in the Treatment of NASH and Liver Fibrosis - Anervea
March 17, 2024 09:19 ET
|
ANERVEA DATA LABS PRIVATE LIMITED
Pune, March 17, 2024 (GLOBE NEWSWIRE) -- The recent FDA approval of Resmetirom, developed by Madrigal Pharmaceuticals, has sent ripples of excitement throughout the medical community, marking a...
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
November 13, 2023 07:00 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
July 17, 2023 07:38 ET
|
ZyVersa Therapeutics
Liver fibrosis is a progressive form of chronic liver injury mediated by persistent NLRP3 inflammasome activation in liver cells called hepatic stellate cells (“HSCs”), which leads to the development...
ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT
January 01, 2021 19:15 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...
Two New Liver Fibrosis Rodent Models Launched by Crown Bioscience
March 10, 2020 08:00 ET
|
Crown Bioscience
SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- Crown Bioscience today announced the launch of two new liver fibrosis rodent models, allowing more rapid and cost-effective evaluation of the...
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
November 13, 2017 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D.,...
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update
November 07, 2017 08:15 ET
|
Galectin Therapeutics Inc.
All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be...